Alport syndrome (AS) is caused by pathogenic mutations in the genes encoding α3, α4 or α5 chains of collagen IV (COL4A3/COL4A4/COL4A5), resulting in hematuria, chronic renal failure (CRF), sensorineural hearing loss (SNHL) and ocular abnormalities. Mutations in the X-linked COL4A5 gene have been identified in 85% of the families (XLAS). In this study, 22 of 60 probands (37%) of unrelated Portuguese families, with clinical diagnosis of AS and no evidence of autosomal inheritance, had pathogenic COL4A5 mutations detected by Sanger sequencing and/or multiplex-ligation probe amplification, of which 12 (57%) are novel. Males had more severe and earlier renal and extrarenal complications, but microscopic hematuria was a constant finding irrespective of gender. Nonsense and splice site mutations, as well as small and large deletions, were associated with younger age of onset of SNHL in males, and with higher risk of CRF and SNHL in females. Pathogenic COL4A3 or COL4A4 mutations were subsequently identified in more than half of the families without a pathogenic mutation in COL4A5. The lower than expected prevalence of XLAS in Portuguese families warrants the use of next-generation sequencing for simultaneous COL4A3/COL4A4/COL4A5 analysis, as first-tier approach to the genetic diagnosis of collagen type IV-related nephropathies.
Alport syndrome (AS) is caused by pathogenic mutations in the genes encoding the α5, α4 or α3 type IV collagen chains (1, 2), respectively, COL4A5, COL4A4 and COL4A3. The selective tissue expression of α5α4α3(IV) heterotrimers explains the renal, cochlear and ocular involvement of AS. Although rare, AS represents an important cause of end-stage renal failure (ESRF), particularly among young adults (1) .
In patients with hematuria of uncertain etiology, the clinical diagnosis of AS can be established whenever at least three of the following criteria are fulfilled (3): family history of macro/microscopic hematuria and/or chronic renal failure (CRF); typical glomerular basement membrane (GBM) lesions on electron microscopy examination; high tone sensorineural hearing loss (SNHL); characteristic ocular abnormalities (anterior lenticonus and/or white macular flecks). Immunohistochemical analysis of expression α5(IV) in the epidermal basement membrane and/or of α5α4α3(IV) in the GBM are additional AS diagnostic tools (2, 3) . However, genetic testing has been accepted as the gold standard for the diagnosis of AS and demonstration of its mode of inheritance (2) .
About 85% of AS families (1) carry pathogenic COL4A5 mutations, causing the X-linked form of the disease (XLAS; MIM#301050). Moreover, AS with diffuse leiomyomatosis (ATS-DL; MIM#308940) and AS with mental retardation, midface hypoplasia and elliptocytosis (AMME; MIM#300194) are two rare syndromes caused by microdeletions involving COL4A5 (1). The remainder of cases, which are due to pathogenic COL4A3 and/or COL4A4 mutations, are inherited as autosomal recessive (ARAS; MIM#2013780) or dominant (ADAS; MIM#104200) disorders. Heterozygous COL4A3 or COL4A4 mutations are identified in 40-50% of patients with thin basement membrane nephropathy (TBMN; MIM#141200).
More than 700 disease-causing COL4A5 mutations, most of them unique to single families, have already been described (4) . Whereas in hemizygous males, complex rearrangements, large and small deletions, nonsense and splice site mutations are associated with more severe phenotype and worse prognosis (5-7), no significant genotype-phenotype correlations could be identified in heterozygous females (8) .
The data available on the molecular pathology of AS in Portugal were from a small number of families enrolled on a European collaborative study (6, 8) . Our major goals are, therefore, to describe the genetic epidemiology and genotype-phenotype correlations in a large nationwide cohort of Portuguese families diagnosed with AS.
Patients and methods
Between 1 January 2009 and 30 June 2012, 60 unrelated patients with at least one of the diagnostic criterion of AS (3), and their affected or at-risk relatives who accepted genetic evaluation, were enrolled in this study for COL4A5 mutational analysis. The research protocol was approved by the Health Ethics Commission of São João Hospital Centre (Porto; Portugal).
The relevant clinical data were collected at enrolment by the referring physician, using a standardized questionnaire. Additional data were retrospectively collected by review of archive medical records, or interviewing patient's relatives. Respectively 5 (8.3%), 17 (28.3%), 26 (43.3%) and 12 (20%) of the probands fulfilled four, three, two and one diagnostic criteria, in addition to hematuria.
Genomic DNA was extracted from whole blood samples. All 53 exons of COL4A5 and corresponding exon/intron boundaries were amplified by polymerase chain reaction (PCR), using previously described primers and conditions (9) . The PCR products were analyzed by Sanger DNA sequencing, using routine laboratory protocols and standard capillary electrophoresis. In addition, a commercial multiplex ligation-dependent probe amplification (MLPA) assay was used to scan for large deletions/duplications involving COL4A5 and the 5 ′ region of COL4A6. Novel variants were considered pathogenic on the basis of molecular, epidemiological, family segregation and/or bioinformatic criteria, as summarized in Table S1 , Supporting Information. Whenever a novel COL4A5 variant of uncertain pathogenicity was identified, or a pathogenic COL4A5 mutation could not be identified in the proband, COL4A3 and COL4A4 were subsequently scanned for pathogenic mutations (20) .
Parental genotyping was carried out, whenever possible, to confirm whether the COL4A5 mutation identified in a proband was inherited or de novo. In cases where the same novel mutation was identified in apparently unrelated probands, microsatellite polymorphic markers flanking the COL4A5-COL4A6 genes were used for haplotype analysis, as previously described (10, 11) .
For genotype-phenotype correlation analyses, COL4A5 mutations were grouped according to the expected severity of the corresponding phenotype (7) . Outcomes were compared between genders and, within each gender, between patients with large rearrangements, frameshifting, nonsense or splice donor mutations ('severe' mutations), and those with other types of mutations ('severe/moderate' mutations). To minimize ascertainment bias, the clinical phenotypes per gender and the genotype-phenotype correlations were analyzed in 'phenotyping cohorts', comprising the probands and their affected relatives subsequently enrolled in this study.
Parametric and non-parametric statistics were used, as appropriate, for comparisons of demographic variables and clinical outcomes. The data were analyzed with the ibm spss Statistics software version 21 (IBM Corporation; Armonk, NY).Results
Twenty-two (37%) of the 60 probands had a pathogenic mutation in COL4A5, of which 12 (57%) were novel and 9 (43%) had been previously described (Table 1) (5, 9, (12) (13) (14) (15) (16) (17) . Eighty percent of the probands who presented with all four diagnostic criteria, but only 1 of 3 of those who presented with two or three criteria, had a pathogenic mutation in COL4A5. Missense substitutions (7/21; 33%), all involving glycine residues, were the most common type of mutation. The novel c.4342G>C (p.Gly1448Arg) missense mutation was identified in two apparently unrelated probands; in the two families, living in neighboring towns, the pathogenic mutation segregated with the same microsatellite haplotype. In 2 of 13 (15%) genetic probands, the COL4A5 mutation was proven to be de novo by parental genotyping.
The identification of a pathogenic COL4A5 mutation allowed confirmation of XLAS in 43 more patients from the 22 families, increasing the size of the phenotyping cohorts to 30 males (46%; mean age 36 ± 16.8 years) and 35 females (54%; mean age 42 ± 14.8 years). Those two cohorts are described and compared in Table 1 . Only two-thirds of the patients had undergone audiological assessment and less than 60% had been referred for specialized ophthalmological examination. This shows that appropriate screening for the extrarenal signs of AS is frequently overlooked in clinical practice (3), which might influence the diagnostic judgment. Expression of renal disease in the male cohort did not substantially differ from the usual description of XLAS in males (6); however, the prevalence of chronic kidney disease (CKD) in the female cohort was higher than previously reported (8) . Microscopic hematuria was present in all cases, irrespective of gender. The risks of developing progressive CKD and ESRF were considerably higher in males (p = 0.029 and p < 0.001, respectively). Nevertheless, CKD was diagnosed in 62% of the heterozygous females, at young adult age in many cases. Electron micrographs of kidney biopsies, available from nine patients, showed the typical ultrastructural features of AS, irrespective of gender. Subjective hearing loss was more often reported by males (87% vs 46%; p = 0.001). Anterior lenticonus and dot-and-fleck retinopathy were also more frequently diagnosed in males (p = 0.013 and p = 0.129, respectively). ATS-DL was diagnosed in one family, in association with a large deletion involving COL4A5, but not the COL4A6 gene (13). In contrast to previous studies (5-7), we did not identify any significant differences on prevalence or severity of expression of renal disease between males carrying 'severe' or 'severe/moderate' COL4A5 mutations, although they manifested more severe extrarenal phenotypes. Conversely, the higher prevalence of CRF and SNHL in females with 'severe' COL4A5 mutations (Table S2) was not apparent in the largest study of females with XLAS reported so far (8) . This genotype-phenotype correlation might have become apparent in our cohort as result of the enrolment of females with more severe renal phenotypes.
Discussion
This is the first study to report the clinical features, molecular pathology and genotype-phenotype correlations observed in a large number of Portuguese patients with genetically confirmed XLAS. A causative COL4A5 mutation was identified in 36.7% (22/60) of the probands. Although this mutation detection rate was significantly lower than expected, it cannot be explained by limitations of the molecular approach, as the sensitivity of Sanger sequencing combined with MLPA to identify COL4A5 mutations is higher than 90% (2, 3). Because we did not exclude enrolment of probands/families without extrarenal manifestations, and the latter are less common in ADAS and absent in TBMN (18), the major explanation for these results can be the higher relative prevalence of autosomal forms of collagen type IV-related GBM nephropathies in Portuguese families with clinical diagnosis of AS (20) . Our data are in agreement with those of a recent Italian study that reported the diagnosis of XLAS in only 2 out of 3 of families with AS confirmed by unbiased next generation sequencing (NGS) (19) . Taken together, these observations suggest that the relative prevalence of XLAS in Southern European populations may be lower than the usual estimates in the literature (1) .
Because of the heterogeneity of the collagen type IV-related GBM nephropathies, clinicians should also take a detailed three-generation family history in order to try to recognize the pattern of inheritance before initiating genetic testing for XLAS (3) . Nonetheless, it should be recognized that XLAS and ARAS may be difficult to distinguish in an affected male with a small pedigree and that some hypomorphic COL4A5 mutations may manifest with microscopic hematuria, with or without ESRF, but with no SNHL or ocular involvement, thereby mimicking TBMN (1) .
Identification of a pathogenic COL4A5 mutation is the most specific criterion for diagnosis of XLAS, avoiding the need for kidney and/or skin biopsies. It is pivotal for family screening and pre-symptomatic diagnosis, with obvious implications for genetic counseling; estimation of the clinical prognosis; selection of living related female donors for kidney transplantation; and prenatal and pre-implantation diagnosis. Genetic diagnosis may also permit the earlier institution of effective nephroprotective therapies, particularly by renin-angiotensin system blockade (2).
However, Sanger sequencing of all 53 COL4A5 exons and flanking intronic sequences is a laborious, time-consuming and expensive process. The recent availability of benchtop NGS platforms has offered the possibility to simultaneously analyze the COL4A5/COL4A4/COL4A3 genes at cheaper costs and with much lower turn-around times (19) . This may become the first-tier genetic testing strategy to confirm the diagnosis of AS, particularly in populations where the prevalence of XLAS is not much higher than that of the autosomal forms.
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